Welcome to our dedicated page for Opthea news (Ticker: OPT), a resource for investors and traders seeking the latest updates and insights on Opthea stock.
Opthea Limited (ASX: OPT) generates frequent news as a clinical-stage biopharmaceutical company developing therapies for retinal diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Company announcements describe the progress of its lead product candidate, sozinibercept, a first-in-class VEGF-C/D ‘trap’ inhibitor studied in combination with standard-of-care anti-VEGF-A therapies.
News items for OPT commonly cover clinical milestones, including Phase 2b and Phase 3 trial updates in wet AMD, early-stage data in DME, and presentations of trial results and subgroup analyses at scientific meetings and in peer-reviewed journals. Opthea also releases updates on manufacturing activities, such as completion of drug substance and drug product Process Performance Qualification campaigns to support potential regulatory filings.
Investors following OPT news will also see corporate and capital markets developments. These include half-year financial reports, cash runway commentary, capital raising outcomes, and details of a Development Funding Agreement and its subsequent settlement. The company has reported that primary endpoints were not met in its COAST and ShORe Phase 3 wet AMD trials and has described the decision, together with its DFA investors, to discontinue development of sozinibercept in wet AMD, along with workforce reductions, management changes, and a planned strategic review.
Regulatory and listing updates also appear in Opthea’s news flow, such as announcements related to its intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market. For readers interested in the intersection of ophthalmology, clinical trial data, and biotech corporate strategy, the OPT news feed provides ongoing context on Opthea’s programs and corporate actions.
Opthea (ASX/NASDAQ:OPT) announced that its wet age-related macular degeneration (wet AMD) therapy, sozinibercept, will be featured in an oral presentation at the FLORetina Congress in Florence, Italy, December 5-8, 2024. The presentation titled 'Beyond VEGF-A Inhibition: Will Blocking VEGF-C and VEGF-D Lead to Better Outcomes?' will be delivered by Professor Adnan Tufail during the Retina Futura 1 session on December 6, 2024, at 11:25 AM CET.
Opthea (ASX/NASDAQ:OPT), a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases including wet age-related macular degeneration, has announced its participation in the Citi 2024 Global Healthcare Conference. CEO Fred Guerard will conduct one-on-one investor meetings and participate in a panel titled 'Eyes Wide Open on Ophthalmology' on December 5, 2024, at 1:45 PM ET in Miami, Florida. The presentation will be available for viewing on the company's website in the Events & Presentations section.
Opthea (ASX/NASDAQ: OPT) announced the appointment of Kathy Connell as Non-Executive Director to its Board, effective November 15, 2024. Connell brings extensive commercial and business development expertise across healthcare industries. The appointment comes as Opthea prepares for Phase 3 wet AMD topline data expected in 2025. Simultaneously, Megan Baldwin retired from the Board as Executive Director but will continue as Founder and Chief Innovation Officer. Connell currently serves as Senior Client Partner at Korn Ferry and holds board positions at Avecho Biotechnology, Proto Axiom, and BioNSW.
Opthea (ASX/NASDAQ: OPT) announced its participation in two major ophthalmology conferences where sozinibercept will be featured. At the 17th Congress of APVRS, Dr. Gregg T. Kokame will present Phase 2b trial data showing that patients with polypoidal choroidal vasculopathy treated with a combination of sozinibercept and ranibizumab achieved significantly better visual and anatomic outcomes compared to ranibizumab alone at 24 weeks. Additionally, CEO Frederic Guerard will present at the Ophthalmology Innovation Summit XIV during the Retina Innovation Showcase.
Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases including wet AMD, has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Virtual Bell Potter Healthcare Conference on November 18, 2024, at 3:00 PM AEDT, with CEO Frederic Guerard delivering the presentation. Additionally, Guerard will participate in one-on-one meetings at the Jefferies London Healthcare Conference on November 19, 2024. The Bell Potter presentation will be available for viewing in the Investor Relations section of Opthea's website.
Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company developing therapies for retinal diseases, has filed its Notice of Annual General Meeting. Dr. Megan Baldwin, Executive Director, will retire from the Board at the conclusion of the annual general meeting on November 15, 2024, and has chosen not to seek re-election. Dr. Baldwin will continue her role as Founder and Chief Innovation Officer, focusing on advancing Opthea's innovation agenda.
The company is approaching anticipated sozinibercept wet AMD Phase 3 data readouts in 2025. Dr. Baldwin expressed pride in sozinibercept's potential as a breakthrough for wet AMD patients. Chairman Jeremy Levin acknowledged Dr. Baldwin's valuable contributions to the Board. Opthea is currently seeking a new director to fill the upcoming Board vacancy.
Opthea (ASX/NASDAQ: OPT) announced that its wet age-related macular degeneration (wet AMD) program will be presented at the Innovate Retina Meeting on October 17, 2024, in Chicago, Illinois. Dr. David Boyer will provide an update on sozinibercept, highlighting:
- The unmet medical need in wet AMD
- Phase 2b trial results
- Phase 3 program designed to assess superiority in visual acuity of the combination therapy with sozinibercept over anti-VEGF-A monotherapy
The presentation, titled 'Update on OPT-302 (sozinibercept)', is scheduled for 5:27 PM CT during Session 4: New Routes and New Molecules. Innovate Retina focuses on innovations in retina care, including AMD management, ocular imaging, gene therapy, and advances in retinal pharmacotherapy.
Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company developing therapies for retinal diseases, has announced three key appointments as it prepares for sozinibercept Phase 3 topline data readouts in 2025:
1. Dr. Parisa Zamiri as Chief Medical Officer (CMO), overseeing clinical development, regulatory affairs, and medical affairs.
2. Tom Reilly as Chief Financial Officer (CFO), bringing over 25 years of experience in finance and administration in life sciences.
3. Anand Sundaram as Vice President Marketing, with extensive commercial experience in retina and other therapeutic areas.
These appointments aim to strengthen Opthea's leadership in preparation for anticipated data readouts from the COAST trial in early Q2 2025 and the ShORe trial in mid-2025, followed by regulatory submissions globally.
Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company focusing on novel therapies for retinal diseases like wet age-related macular degeneration (wet AMD), has announced its participation in the UBS Virtual Ophthalmology Day 2024. The event is scheduled for October 2, 2024.
Key details of Opthea's participation include:
- A fireside chat on Wednesday, October 2, 2024, at 4:00 PM ET
- CEO Frederic Guerard, PharmD, will be the presenter
- One-on-one investor meetings will be available
- A webcast link is provided for access to the fireside chat
The webcast will also be accessible through the 'Events & Presentations' section of Opthea's Investor Relations webpage at www.opthea.com.
Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company developing therapies for retinal diseases, has been added to the S&P/ASX 300 Index effective September 23, 2024. This inclusion reflects the company's strengthened balance sheet following a financing round in July 2024 and the completion of enrollment for its Phase 3 wet AMD program with nearly 2,000 patients.
CEO Frederic Guerard highlighted that joining the index may diversify Opthea's institutional shareholder base as the company progresses towards anticipated topline data readouts from its COAST and ShORe trials in Q2 and mid-2025, respectively. The company is also preparing for a potential US FDA approval and product launch.
The S&P/ASX 300 Index measures the performance of 300 of Australia's largest securities by float-adjusted market capitalization, encompassing large-cap, mid-cap, and small-cap components.
FAQ
What is the current stock price of Opthea (OPT)?
What is the market cap of Opthea (OPT)?
